Association Between Serum Amyloid-Beta and Renal Functions: Implications for Roles of Kidney in Amyloid-Beta Clearance

被引:0
作者
Yu-Hui Liu
Yang Xiang
Ye-Ran Wang
Shu-Sheng Jiao
Qing-Hua Wang
Xian-Le Bu
Chi Zhu
Xiu-Qing Yao
Brian Giunta
Jun Tan
Hua-Dong Zhou
Yan-Jiang Wang
机构
[1] Third Military Medical University,Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital and Institute of Field Surgery
[2] University of South Florida,Neuroimmunology Laboratory, Morsani College of Medicine
[3] University of South Florida,Rashid Laboratory for Developmental Neurobiology, Silver Child Development Center, Department of Psychiatry and Behavioral Neurosciences, Morsani College of Medicine
来源
Molecular Neurobiology | 2015年 / 52卷
关键词
Chronic kidney disease; Aβ; Peripheral clearance; Alzheimer’s disease;
D O I
暂无
中图分类号
学科分类号
摘要
Amyloid-beta (Aβ) plays a central role in the pathogenesis of Alzheimer’s disease (AD), and it is a major therapeutic target for AD. It is proposed that removal of Aβ in blood can facilitate Aβ clearance from the brain, representing a promising therapeutic approach for AD. However, the efficacy and mechanisms for Aβ clearance by peripheral organs and tissues remain largely unknown. In the present study, 47 chronic kidney disease (CKD) patients (16 newly diagnosed patients who had never been dialyzed and 31 patients who were receiving dialysis) and 43 normal controls (NC) were enrolled. We found that serum Aβ levels were significantly higher in CKD patients than NC. CKD patients who were receiving dialysis had lower serum Aβ levels than patients without receiving dialysis, being comparable to NC. Furthermore, serum Aβ levels were correlated with renal functions reflected by estimated glomerular filtration rate (eGFR) and residual GFR (rGFR). Our study suggests that kidney is involved in peripheral clearance of Aβ, and dialysis might be a potential therapeutic approach of Aβ removal.
引用
收藏
页码:115 / 119
页数:4
相关论文
共 21 条
[1]  
Coresh J(2007)Prevalence of chronic kidney disease in the United States JAMA 298 2038-2047
[2]  
James BD(2014)Contribution of Alzheimer disease to mortality in the United States Neurology 82 1045-1050
[3]  
Lemere CA(2003)Evidence for peripheral clearance of cerebral Abeta protein following chronic, active Abeta immunization in PSAPP mice Neurobiol Dis 14 10-18
[4]  
Wang YJ(2014)Alzheimer disease: Lessons from immunotherapy for Alzheimer disease Nat Rev Neurol 10 188-189
[5]  
Liu YH(2012)Immunotherapy for Alzheimer disease: the challenge of adverse effects Nat Rev Neurol 8 465-469
[6]  
Miwa K(2014)Chronic kidney disease is associated with dementia independent of cerebral small-vessel disease Neurology 82 1051-1057
[7]  
Li J(2011)Vascular risk factors promote conversion from mild cognitive impairment to Alzheimer disease Neurology 76 1485-1491
[8]  
Levey AS(2009)A new equation to estimate glomerular filtration rate Ann Intern Med 150 604-612
[9]  
Hoek FJ(2007)Estimation of residual glomerular filtration rate in dialysis patients from the plasma cystatin C level Nephrol Dial Transplant 22 1633-1638
[10]  
Wang YJ(2006)Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives Drug Discov Today 11 931-938